Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas Ended Scholarship Donation to Clear Up Doubts on Inducing Prescriptions, No Major Issues Seen after 1 Year
April 8, 2021
- Japan Ethical Drug Sales Fall 2.8% in FY2020: Encise
April 8, 2021
- HUYA Files HBI-8000 for PTCL in Japan: Meiji
April 8, 2021
- Japan Ethical Drug Sales Down 3.8% in February: Crecon
April 8, 2021
- Shonan iPark Partners with UK Bioscience Hub
April 7, 2021
- Takeda Sees FY2021 as Inflection Year for Pipeline, 4 Potential Approvals from 6 Submission-Planned Assets
April 7, 2021
- AstraZeneca's COVID-19 Vaccine as Effective for UK Variant:Exec
April 7, 2021
- AstraZeneca Looks to Become Top Drug Maker in Japan by 2025
April 7, 2021
- Daiichi Sankyo Looks to Rack Up Sales of 1.6 Trillion Yen in FY2025, 3 ADCs as Drivers
April 6, 2021
- Astellas, Toa Eiyo to End Sales Collaboration in March 2022
April 6, 2021
- Kowa Seeks 5.6 Billion Yen in Add’l Damages from Towa over Livalo Generics
April 6, 2021
- Viatris Launches New Headquarters in Tokyo
April 6, 2021
- Toho to Supply Nafamostat Free of Charge to Italian Physician-Led COVID-19 Trial
April 6, 2021
- Mochida’s Updated 3-Year Biz Plan Vows Continued Focus on New Meds
April 5, 2021
- Suzuken Unit Wins Wholesale Contract for Incyte’s Pemazyre
April 5, 2021
- Taiho’s Cholangiocarcinoma Drug Gets Breakthrough Therapy Tag from FDA
April 5, 2021
- Houng Kim to Lead Celltrion Healthcare Japan
April 5, 2021
- Takeda/CSL-Led Alliance’s COVID-19 Plasma Therapy Fails in PIII
April 5, 2021
- GSK Sees Promise in Antibody Therapy against Coronavirus Variants, Looking at Japan Rollout Too
April 2, 2021
- Alinamin Aims for Growth via Retail Promotion, Full Entry into Asia: President
April 2, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…